Pharming Group (OTCMKTS:PHGUF) Sets New 1-Year High – Here’s What Happened

Shares of Pharming Group NV (OTCMKTS:PHGUF) reached a new 52-week high during trading on Friday . The stock traded as high as $1.85 and last traded at $1.85, with a volume of 450 shares changing hands. The stock had previously closed at $1.65.

Pharming Group Stock Performance

The stock has a market cap of $1.11 billion, a PE ratio of 185.19 and a beta of 0.37. The stock has a fifty day moving average of $1.63 and a 200-day moving average of $1.43. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.46.

Pharming Group (OTCMKTS:PHGUF) last issued its earnings results on Thursday, November 6th. The biotechnology company reported $0.01 earnings per share for the quarter. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The business had revenue of $97.30 million for the quarter, compared to the consensus estimate of $80.18 million.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.